The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...
In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...
“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...
CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition streng...
The acquisition is expected to close on February 1, 2024, subject to customary closing conditions. By bringing the Precise Tumor and Precise Liquid tests i...
Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth a...
Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-re...
MoBiTec will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, enhancing its sales capabilities and product range for custome...
Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights for Greater Chinaand Singapore Transaction reflects the&...
“We are pleased with the outcome of today’s Special Meeting and thank our stockholders for their support for this merger,” said Michael E...
Dr. Reddy’s acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address s...
Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces that it has acquired Replace Therapeutics Inc., a private biote...
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coa...
"Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this sp...
© 2025 Biopharma Boardroom. All Rights Reserved.
